Nonfamilial medullary thyroid carcinoma

Rossi, Ricardo L.; Cady, Blake; Meissner, William A.; Wool, Marvin S.; Sedgwick, Cornelius E.; Werber, Joan

doi:10.1016/0002-9610(80)90337-2

Cited by 51 publications

(18 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Age has also been asserted to be an important predictor of the course of medullary carcinomas (4,18). In the present report, however, age at diagnosis was neither correlated to a poor prognosis nor to locally advanced disease.…”

Section: Discussioncontrasting

confidence: 52%

“…The prognostic importance of local extension has also been asserted in other reports (4, 18,24). In most patients, there is a positive correlation between plasma calcitonin and the measured thyroid tumour mass at the time of surgery (24), but, in a few patients with tumours showing cellular heterogeneity, there is a discordance between tumour size and plasma calcitonin (15).…”

Section: Discussionmentioning

confidence: 58%

“…(23) analysed some parameters for 153 patients with well-differentiated carcinomas with a longer period of follow-up. The justification of a long follow-up is that late recurrence of differentiated carcinomas is not unusual (12,18,19).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Prognostic Factors of Papillary, Follicular and Medullary Carcinomas of the Thyroid Gland: Retrospective multivariate analysis of 216 patients with a median follow-up of 11 years

Tennvall

Biörklund

Möller

et al. 1985

Acta Radiologica: Oncology

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 52%

Section: Discussionmentioning

confidence: 58%

See 1 more Smart Citation

Prognostic Factors of Papillary, Follicular and Medullary Carcinomas of the Thyroid Gland: Retrospective multivariate analysis of 216 patients with a median follow-up of 11 years

Tennvall

Biörklund

Möller

et al. 1985

Acta Radiologica: Oncology

View full text Add to dashboard Cite

“…This surgical strategy is widely accepted in patients with non palpable MTC identified by screening, but the need for more extensive neck dissection at first surgery remains a matter of debate in those who present a palpable mass. MTC gives early metastases to regional nodes; several reports state that cervical involvement occurs in 25-63% of cases, depending on the series considered (Hazard et al 1959, Willliams 1966, Chong et al 1975, Rossi et al 1980, Rougier et al 1983. In patients with palpable unilateral MTC, Moley and DeBenedetti (1999) found lymph node metastases in 81% of central neck dissection specimens, in 81% of ipsilateral neck dissection specimens, and in 44% of contralateral neck dissection specimens.…”

Section: Surgical Treatmentmentioning

confidence: 99%

Treatment of medullary thyroid carcinoma: an update.

Orlandi¹,

Caraci²,

Mussa³

et al. 2001

Endocrine-Related Cancer

View full text Add to dashboard Cite

Prognosis and treatment effectiveness of medullary thyroid carcinoma (MTC) are largely related to the tumour stage, so that early diagnosis represents an important goal for the management of patients. Recent advances in genetic testing have improved the clinical approach to the familial MTC syndromes. There is general agreement that the primary operation for MTC should obtain the complete removal of the neoplastic tissue in the neck, because any adjuvant treatment has never been proven to be effective. The management of residual/recurrent or metastatic MTC still remains controversial, although a multimodal approach to advanced disease may be of value in palliation or local control of tumour progression. The role of surgery, external radiotherapy, radionuclide therapy and medical treatment, including biological response modifiers and cytotoxic drugs, are reviewed and discussed.

show abstract

“…Both the sporadic and the familial form are treated by surgery (Chong et al, 1975;Rossi et al, 1980), as the efficacy of radiotherapy is limited (Samaan et al, 1988) and chemotherapy is ineffective (Rougier et al, 1983;Brunt and Wells, 1987). Early diagnosis of recurrence or metastasis and accurate localisation of recurrent disease are very important prerequisites for successful surgical excision.…”

mentioning

confidence: 99%

Pretargeted immunoscintigraphy in patients with medullary thyroid carcinoma

Magnani

Paganelli²,

Songini³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

Summary To evaluate the use of pretargeted immunoscintigraphy (ISG) in the diagnosis and follow-up of patients with medullary thyroid carcinoma (MTC), we studied 25 patients with histologically proven disease; ISG was repeated after surgery in two patients. The antibody, either an anticarcinoembryonic antigen (CEA) or an antichromogranin A (CgA) biotinylated monoclonal antibody (MAb) or a cocktail of the two biotinylated MAbs was first injected. After 24 h, avidin was administrated i.v., followed by "'In-labelled biotin 24 h later. Fifty-two lesions were visualised. Six primary tumours, diagnosed by increased calcitonin levels, were all correctly diagnosed; 47 recurrences, also suspected by blood tumour markers, were detected and confirmed by cytology or histology. In one case, single photon emission tomography allowed the detection of small lymph nodes with a diameter of 4 -7 mm. These lesions, not judged neoplastic by ultrasound, were confirmed to be neoplastic by fine needle aspiration. Pretargeted ISG correctly localises primary tumours and recurrences in MTC patients, when the only marker of relapse is serum elevation of calcitonin. With this three-step pretargeting method, cocktails of potentially useful MAbs can be used, avoiding false-negative studies that may occur when CEA or CgA are not expressed.Keywords: medullary thyroid carcinoma; monoclonal antibody; avidin-biotin Medullary thyroid carcinoma (MTC) arises from calcitoninsecreting parafollicular cells in the thyroid. Both the sporadic and the familial form are treated by surgery (Chong et al., 1975;Rossi et al., 1980), as the efficacy of radiotherapy is limited (Samaan et al., 1988) and chemotherapy is ineffective (Rougier et al., 1983;Brunt and Wells, 1987). Early diagnosis of recurrence or metastasis and accurate localisation of recurrent disease are very important prerequisites for successful surgical excision.Elevated serum calcitonin (Ct) is considered to be a marker for MTC. High serum levels of Ct and carcinoembryonic antigen (CEA) can often be found in patients with recurrent disease several years before it becomes clinically apparent, but, at present, no efficient and specific method is available for the localisation of recurrences.Morphological imaging techniques (ultrasonography, US; computerised tomography, CT; magnetic resonance imaging, MRI) are routinely used to confirm and localise a biologically detected recurrence but are not always adequate because of topographic polymorphism and the small size of tumour recurrences at an early stage of development (Schwerk et al., 1985;Frank et al., 1987;Crow et al., 1989).Several methods based on tumour avidity of non-specific radiopharmaceuticals such as [99"Tc](V)DMSA, '3I11231-MIBG and 20'T1 have also been designed for this purpose, with variable results (Arnstein et al., 1986;Hilditch et al., 1986;Baulieu et al., 1987;Clarke et al., 1987;Hilditch, 1987; Clarke et al., 1988;Hoefnagel et al., 1988;Guerra et al., 1989;Adams et al., 1990;Charkes et al., 1990;Udelsman et al., 1993).In the attem...

show abstract

Nonfamilial medullary thyroid carcinoma

Cited by 51 publications

References 34 publications

Prognostic Factors of Papillary, Follicular and Medullary Carcinomas of the Thyroid Gland: Retrospective multivariate analysis of 216 patients with a median follow-up of 11 years

Prognostic Factors of Papillary, Follicular and Medullary Carcinomas of the Thyroid Gland: Retrospective multivariate analysis of 216 patients with a median follow-up of 11 years

Treatment of medullary thyroid carcinoma: an update.

Pretargeted immunoscintigraphy in patients with medullary thyroid carcinoma

Contact Info

Product

Resources

About